- Home
- NGNE vs ATNI Comparison
NGNE vs ATNI Comparison
Compare NGNE & ATNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NGNE
- ATNI
- Stock Information
- Founded
- NGNE 2003
- ATNI 1987
- Country
- NGNE United States
- ATNI United States
- Employees
- NGNE N/A
- ATNI N/A
- Industry
- NGNE Biotechnology: Pharmaceutical Preparations
- ATNI Telecommunications Equipment
- Sector
- NGNE Health Care
- ATNI Telecommunications
- Exchange
- NGNE Nasdaq
- ATNI Nasdaq
- Market Cap
- NGNE 251.9M
- ATNI 240.0M
- IPO Year
- NGNE N/A
- ATNI 1991
- Fundamental
- Price
- NGNE $15.42
- ATNI $16.34
- Analyst Decision
- NGNE Strong Buy
- ATNI Strong Buy
- Analyst Count
- NGNE 7
- ATNI 1
- Target Price
- NGNE $41.86
- ATNI $30.00
- AVG Volume (30 Days)
- NGNE 193.9K
- ATNI 47.4K
- Earning Date
- NGNE 08-08-2025
- ATNI 07-23-2025
- Dividend Yield
- NGNE N/A
- ATNI 6.01%
- EPS Growth
- NGNE N/A
- ATNI N/A
- EPS
- NGNE N/A
- ATNI N/A
- Revenue
- NGNE $925,000.00
- ATNI $721,575,000.00
- Revenue This Year
- NGNE N/A
- ATNI $2.03
- Revenue Next Year
- NGNE N/A
- ATNI $1.59
- P/E Ratio
- NGNE N/A
- ATNI N/A
- Revenue Growth
- NGNE N/A
- ATNI N/A
- 52 Week Low
- NGNE $6.88
- ATNI $13.76
- 52 Week High
- NGNE $74.49
- ATNI $33.72
- Technical
- Relative Strength Index (RSI)
- NGNE 40.98
- ATNI 58.94
- Support Level
- NGNE $19.13
- ATNI $15.89
- Resistance Level
- NGNE $18.21
- ATNI $16.66
- Average True Range (ATR)
- NGNE 1.59
- ATNI 0.51
- MACD
- NGNE -0.59
- ATNI 0.12
- Stochastic Oscillator
- NGNE 4.26
- ATNI 90.13
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
About ATNI ATN International Inc.
ATN International Inc is a telecommunications and utilities company. The company provides digital infrastructure and communications services with a focus on rural and remote markets in the United States, and internationally, including Bermuda and the Caribbean region. Its operating segments comprise U.S. Telecom and International Telecom. The company earns revenue from its International telecommunication segment.